Paper2953239
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
Leenen FH and 4 others. Am J Med, 1987. Cited by 121 papers, by iCite.
Cite this record
ConductScience Library. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Papers, record 2953239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2953239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiomegaly | Major topic |
| Hydralazine | Major topic |
| Hypertension | Major topic |
| Prazosin | Major topic |
| Vasodilator Agents | Major topic |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 121 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39680249 | Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications. | Curr Hypertens Rep | 2024 | https://conductscience.org/library/papers/39680249 | PubMed |
| 34515895 | The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof. | Cardiovasc Drugs Ther | 2023 | https://conductscience.org/library/papers/34515895 | PubMed |
| 34054559 | The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34054559 | PubMed |
| 24790136 | Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. | Arterioscler Thromb Vasc Biol | 2014 | https://conductscience.org/library/papers/24790136 | PubMed |
| 20136844 | Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. | Br J Pharmacol | 2010 | https://conductscience.org/library/papers/20136844 | PubMed |
| 8762091 | Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. | Br J Pharmacol | 1996 | https://conductscience.org/library/papers/8762091 | PubMed |
| 3254831 | Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension. | Drugs | 1988 | https://conductscience.org/library/papers/3254831 | PubMed |
| 3191000 | Topical minoxidil: cardiac effects in bald man. | Br J Clin Pharmacol | 1988 | https://conductscience.org/library/papers/3191000 | PubMed |
| 2535100 | Left ventricular mass changes with nicardipine therapy in essential hypertension. | Cardiovasc Drugs Ther | 1989 | https://conductscience.org/library/papers/2535100 | PubMed |
| 2149513 | Left ventricular hypertrophy reversal with labetalol and propranolol: a prospective randomized, double-blind study. | Cardiovasc Drugs Ther | 1990 | https://conductscience.org/library/papers/2149513 | PubMed |
| 1981020 | Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. | Cardiovasc Drugs Ther | 1990 | https://conductscience.org/library/papers/1981020 | PubMed |
| 1724641 | Regression of increased left ventricular mass by antihypertensives. | Drugs | 1991 | https://conductscience.org/library/papers/1724641 | PubMed |
| 1687998 | Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more? | Clin Auton Res | 1991 | https://conductscience.org/library/papers/1687998 | PubMed |
| 1390327 | Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy. | Cardiovasc Drugs Ther | 1992 | https://conductscience.org/library/papers/1390327 | PubMed |
| 1290920 | A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. | Clin Auton Res | 1992 | https://conductscience.org/library/papers/1290920 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2A1 | 597 | PubTator's text mining | https://conductscience.org/library/genes/597 | NCBI Gene |
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2953239
GET https://conductscience.org/api/papers/v1/2953239/authors